Traditionally, it is believed that SGLT2 inhibitors induce DKA primarily through the following mechanisms: 1) SGLT2 inhibitors predominantly act on the kidneys, leading to substantial glucose excretion via urine, which increases the risk of urinary tract infections (UTIs) and may subsequently induce DKA. This evidence concerns the gene SLC5A2 and urinary tract infection.